{"id":"ldx-treatment","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Decreased appetite"},{"rate":"20-30","effect":"Insomnia"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Anxiety"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"5-15","effect":"Increased heart rate"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":{"chemblId":"CHEMBL592496","moleculeType":"Small molecule","molecularWeight":"916.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LDX is an inactive compound that requires hepatic metabolism to release active d-amphetamine. Once converted, d-amphetamine acts as a sympathomimetic amine by stimulating the release of catecholamines (norepinephrine and dopamine) from nerve terminals and inhibiting their reuptake, leading to increased synaptic concentrations. This mechanism enhances attention, focus, and impulse control while reducing hyperactivity and impulsivity.","oneSentence":"LDX (lisdexamfetamine) is a prodrug that is metabolized to d-amphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:49.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"},{"name":"Moderate to severe binge eating disorder"}]},"trialDetails":[{"nctId":"NCT07337239","phase":"NA","title":"Assessment of the Effect of Hypoglossal Nerve Stimulation Therapy on Upper Airway Collapsibility During Drug-induced Sleep Endoscopy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-01","conditions":"Obstructive Sleep Apnea","enrollment":21},{"nctId":"NCT03946111","phase":"PHASE2, PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-08-07","conditions":"Binge-Eating Disorder, Obesity","enrollment":3},{"nctId":"NCT03926052","phase":"PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-08-07","conditions":"Binge-Eating Disorder, Obesity","enrollment":61},{"nctId":"NCT01071044","phase":"PHASE4","title":"Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome","status":"COMPLETED","sponsor":"Rochester Center for Behavioral Medicine","startDate":"2009-11","conditions":"Chronic Fatigue Syndrome, Cognitive Impairments","enrollment":26},{"nctId":"NCT04899271","phase":"PHASE2","title":"A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2020-12-14","conditions":"New-onset Type 1 Diabetes","enrollment":25},{"nctId":"NCT05368402","phase":"PHASE2","title":"Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-09-14","conditions":"Type 1 Diabetes","enrollment":3},{"nctId":"NCT05957055","phase":"PHASE2","title":"Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-02-05","conditions":"Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT03924193","phase":"PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-03-25","conditions":"Binge-Eating Disorder, Obesity","enrollment":141},{"nctId":"NCT02029989","phase":"NA","title":"Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-02","conditions":"Hyperlipidemia, Diabetes, Hypertension","enrollment":121},{"nctId":"NCT03337646","phase":"PHASE4","title":"Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism","status":"COMPLETED","sponsor":"JPM van Stralen Medicine Professional","startDate":"2018-09-26","conditions":"Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder","enrollment":48},{"nctId":"NCT04854642","phase":"PHASE1","title":"A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2020-10-20","conditions":"no Condition","enrollment":36},{"nctId":"NCT05035368","phase":"PHASE2","title":"Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2021-09-30","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT02259517","phase":"NA","title":"An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":38},{"nctId":"NCT01913912","phase":"PHASE3","title":"Event Rate and Effects of Stimulants in ADHD","status":"WITHDRAWN","sponsor":"University Ghent","startDate":"2014-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT01738698","phase":"PHASE3","title":"Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2012-11-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT01760889","phase":"PHASE3","title":"SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT01760993","phase":"PHASE3","title":"Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT01235338","phase":"PHASE1","title":"Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-28","conditions":"Healthy","enrollment":80},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT00905424","phase":"PHASE2","title":"Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-30","conditions":"Major Depressive Disorder","enrollment":246},{"nctId":"NCT01657019","phase":"PHASE3","title":"Open Label Extension in Adults With Binge Eating Disorder (BED)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-08-21","conditions":"Binge Eating Disorder","enrollment":604},{"nctId":"NCT01274221","phase":"PHASE3","title":"Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"WITHDRAWN","sponsor":"Shire","startDate":"2011-03-06","conditions":"ADHD","enrollment":""},{"nctId":"NCT01234298","phase":"PHASE3","title":"SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia","status":"WITHDRAWN","sponsor":"Shire","startDate":"2012-01-27","conditions":"Negative Symptoms of Schizophrenia","enrollment":""},{"nctId":"NCT00736255","phase":"NA","title":"Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-12","conditions":"Attention Deficit Hyperactivity Disorder, Nicotine Dependence","enrollment":32},{"nctId":"NCT01070394","phase":"PHASE4","title":"Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2010-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":40},{"nctId":"NCT01986777","phase":"NA","title":"LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2013-07","conditions":"Cognitive Impairments, RRSO","enrollment":""},{"nctId":"NCT01986764","phase":"NA","title":"E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2013-07-01","conditions":"Planned RRSO","enrollment":""},{"nctId":"NCT01959646","phase":"NA","title":"The Effect of AGE on the Immune System","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-01","conditions":"Healthy","enrollment":91},{"nctId":"NCT02659488","phase":"PHASE2","title":"Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects","status":"UNKNOWN","sponsor":"Lindner Center of HOPE","startDate":"2015-09","conditions":"Binge Eating Disorder","enrollment":40},{"nctId":"NCT00753012","phase":"PHASE4","title":"Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vyvanse"],"phase":"marketed","status":"active","brandName":"LDX Treatment","genericName":"LDX Treatment","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LDX (lisdexamfetamine) is a prodrug that is metabolized to d-amphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Moderate to severe binge eating disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}